Head to Head Review: CARGO Therapeutics (CRGX) vs. Its Rivals

CARGO Therapeutics (NASDAQ:CRGX) is one of 295 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare CARGO Therapeutics to similar businesses based on the strength of its valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Valuation and Earnings

This table compares CARGO Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CARGO Therapeutics	N/A	-$98.15 million	-3.99
CARGO Therapeutics Competitors	$551.75 million	-$35.20 million	3.30

CARGO Therapeutics’ rivals have higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares CARGO Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CARGO Therapeutics	N/A	-38.07%	-33.87%
CARGO Therapeutics Competitors	-4,822.22%	-158.01%	-43.30%

Insider & Institutional Ownership

93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 1.4% of CARGO Therapeutics shares are owned by company insiders. Comparatively, 15.9% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for CARGO Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CARGO Therapeutics	0	0	7	0	3.00
CARGO Therapeutics Competitors	1713	5033	13118	255	2.59

CARGO Therapeutics currently has a consensus target price of $30.33, indicating a potential upside of 78.43%. As a group, “Biological products, except diagnostic” companies have a potential upside of 65.13%. Given CARGO Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe CARGO Therapeutics is more favorable than its rivals.

Summary

CARGO Therapeutics beats its rivals on 7 of the 12 factors compared.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.